$2.09
-0.01 (-0.48%)
Open$2.06
Previous Close$2.10
Day High$2.16
Day Low$2.03
52W High$3.43
52W Low$0.41
Volume—
Avg Volume176.1K
Market Cap133.83M
P/E Ratio—
EPS$-0.54
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+565.6% upside
Current
$2.09
$2.09
Target
$13.91
$13.91
$12.64
$13.91 avg
$18.47
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 7.04M | 7.06M | 6.30M |
| Net Income | 1.07M | 1.40M | 1.10M |
| Profit Margin | 15.2% | 19.8% | 17.5% |
| EBITDA | 1.93M | 2.06M | 1.69M |
| Free Cash Flow | 1.16M | 752.4K | 1.14M |
| Rev Growth | -2.7% | +19.8% | -1.2% |
| Debt/Equity | 1.45 | 1.09 | 1.43 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |